Assay Report Card

Basic Information

ID: ALA3888223

Type: Binding

Description: Discontinuous Radiometric Assay: Compounds may be evaluated as selective reversible inhibitors of AKR1C3 by screening them against homogeneous recombinant AKR1C1-AKR1C4 expressed in E. coli. In each case, a discontinuous radiometric assay may be used to monitor the inhibition of progesterone reduction (20-ketosteroid reduction) catalyzed by AKR1C1, the inhibition of Δ4-AD reduction (17-ketosteroid reduction) catalyzed by AKR1C3, and the inhibition of 5α-DHT reduction (3-ketosteroid reduction) catalyzed by AKR1C2 and AKR1C4 (by measuring the formation of 20α-hydroxyprogesterone, testosterone or 3α-androstanediol by radiochromatography). Secondary screens of the compounds of interest include: (a) a full-screen against all nine human recombinant AKR enzymes to ensure there are no-intended off-target effects (in this context AKR1B10 (retinal reductase; SEQ ID NO:5) has been shown to be potently inhibited by N-phenylanthranilates) (Endo et al., 2010, Biol. Pharm. Bull. 33:886-90); (b) a screen against COX-1 and COX-2 to reaffirm that compounds do not act as NSAIDs; and (c) an expanded screen against other nuclear receptors (especially other steroid hormone receptors).

Organism: Homo sapiens

Activity Charts

Compound Summary

Parent Molecular WeightALogPPolar Surface Area
357.793.933.93
284.753.153.15
281.234.154.15
213.243.133.13
386.534.664.66
238.243.173.17
210.272.412.41
415.573.153.15
213.243.133.13
213.243.133.13
258.233.043.04
255.273.333.33
281.234.154.15
247.683.783.78
292.133.893.89
269.344.434.43
243.263.143.14
227.263.443.44
349.223.483.48
356.813.633.63
326.234.064.06
162.192.172.17
288.263.053.05
322.324.284.28
303.232.942.94
299.283.033.03
395.544.744.74